Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
about
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk PatientsAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal StudyGerman Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.Two cases of mastectomy after Paclitaxel + bevacizumab therapy for locally advanced breast cancerOutcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Chemotherapy in early breast cancer: when, how and which one?AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.Investigations for patients with early-stage breast cancer: oversetting the stage.Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.The Globalization of Cooperative Groups.Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.Advances in the approach to novel drug clinical development for breast cancer.The development of dose-dense adjuvant chemotherapy.Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes.Biology and Management of Patients With Triple-Negative Breast Cancer.Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer.Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.Reply to E.J. Moylan et al.Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.Should age impact breast cancer management in young women? Fine tuning of treatment guidelines.Overview of Breast Cancer Therapy
P2860
Q26751253-C38FD1CF-61CD-4726-AB40-0281646BC972Q26853619-690B4C98-EA04-4B22-B4F6-6CA5B18DFBF3Q27343148-ECF8DCDC-E74C-423B-B1B9-0E833125BB10Q28383479-35BBD94B-F3B8-43CD-9D2C-B49E97C132D9Q30313214-3FBC8D32-A61D-4D46-B0E0-AF97A6F961DEQ33418714-A54D0883-7AB9-4544-A156-344DBEA848E5Q33432594-09686B98-E9FA-4F2D-A8FB-C601C2CF2D0FQ33724674-D957050A-C3BE-40D4-B963-A275623A90CDQ33824842-778A8116-4816-4DED-82B9-070CCF7EDC1DQ34042627-5076A96A-F702-4BD7-A37D-4BDED4DCCB63Q34042640-FF854E3C-21D6-4445-8910-9D86E0F11F56Q34042768-01EB9CA1-3425-45FF-8039-B822704A9A0EQ34716590-3D0506F1-0BB0-462A-B7A9-E93F69D166B7Q35671431-3E685C81-EDA4-432A-AA9A-0268237A6886Q35678397-B704C26D-2ACC-431E-8244-CA608952214BQ35786472-493F7275-89A8-4543-8467-147ACB3CBFBDQ36119749-11136447-E764-490C-8C39-4D09266C9C92Q36379148-497FE8B6-6E3F-4C5C-910D-5CB16C8F65EEQ36463767-B9093512-4203-4037-BC2E-499F15BD0543Q38206546-0ADB03F6-F07C-4AFD-9B7E-2C637FF4DD88Q38296287-887EA398-07CE-46C8-8C88-2A8A8178BC14Q38395226-C8F66B5D-7DF8-4F9D-93C8-0147058E12E8Q38445535-3FDF11D7-9BDE-4CB0-9F6C-D43ED6BFC5D0Q38682028-CCB68D84-1E3D-4F02-900F-D585D90722F9Q38882550-870FECA8-93CB-43A8-9642-5788CF0662FDQ38893074-EC6382FF-BB04-4A7D-B8DC-82157BEFA548Q40364449-E00CE4E3-0350-4E6C-85BC-7FD59B9974EFQ40768663-E0F7118C-9FAD-4948-84DC-594F8586603CQ41706289-D37FF016-DAD6-4E6E-914C-706EB07351A0Q42556142-880598E6-CB66-4E20-A507-96FB2133A241Q44834419-3F86E995-3D3B-4D83-ADE2-85690701744AQ45056867-047CCA2F-C2C5-4A88-BFCE-2B91DB6C25B9Q46192794-59670FCF-7E51-4518-BF66-CD3E47B1A315Q47391721-76C9420C-D222-4D3F-86F6-9E5DA62C7A24Q50221869-E83B360A-5BB1-436B-9A76-0E1947E112B8Q51841285-33F925AD-644F-4AF2-BEBC-9B12014D63F0Q55026521-268AEF35-F5C3-47CA-986F-A464E511562DQ55431604-E52643F2-F59D-475B-A46B-B01162ED667DQ57110718-BEC9BC2E-8D73-474F-B9A3-70679926FF8C
P2860
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@en
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@nl
type
label
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@en
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@nl
prefLabel
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@en
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@nl
P2093
P2860
P356
P1476
Definitive results of a phase ...... cancer: the NSABP B-38 trial.
@en
P2093
Adam M Brufsky
André Robidoux
Catherine A Azar
Charles E Geyer
David D Biggs
Donald W Northfelt
Edward A Levine
Eleftherios P Mamounas
James N Atkins
P2860
P304
P356
10.1200/JCO.2012.48.1275
P407
P577
2013-08-12T00:00:00Z